Los Angeles Capital Management LLC Has $568,000 Position in Harrow, Inc. (NASDAQ:HROW)

Los Angeles Capital Management LLC trimmed its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 60.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,918 shares of the company’s stock after selling 26,191 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Harrow were worth $568,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of Harrow by 2.2% during the third quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after buying an additional 15,554 shares in the last quarter. Geode Capital Management LLC increased its holdings in Harrow by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock worth $32,500,000 after purchasing an additional 3,960 shares in the last quarter. Braidwell LP boosted its stake in shares of Harrow by 47.9% during the third quarter. Braidwell LP now owns 439,638 shares of the company’s stock valued at $19,766,000 after purchasing an additional 142,450 shares in the last quarter. First Turn Management LLC bought a new stake in shares of Harrow during the third quarter worth about $14,683,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after buying an additional 166,602 shares during the period. Institutional investors own 72.76% of the company’s stock.

Harrow Stock Performance

Shares of HROW stock opened at $25.63 on Tuesday. The stock has a market capitalization of $912.81 million, a PE ratio of -27.27 and a beta of 0.69. The business’s 50 day simple moving average is $32.35 and its 200 day simple moving average is $39.93. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a one year low of $9.30 and a one year high of $59.23.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HROW shares. B. Riley cut their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright initiated coverage on shares of Harrow in a report on Thursday, February 6th. They set a “buy” rating and a $57.00 price target on the stock.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.